The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 3, 2009, Pages 319-329

  Cuadrado, Antonio ^a   Moreno Murciano, Paz ^a   Pedraza Chaverri, José ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Catechol; Dopamine; Keap1; Levodopa; Nrf2; Oxidative stress; Parkinson's disease; Quinones

Indexed keywords

1,2 DITHIOLE 3 THIONE DERIVATIVE; 3H 1,2 DITHIOLE 3 THIONE; ANTIOXIDANT; APOMORPHINE; AR A 014418; BROMOCRIPTINE; CARNOSIC ACID; CARNOSOL; CATECHOL; DOPAMINE RECEPTOR STIMULATING AGENT; EPIGALLOCATECHIN GALLATE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; INDIRUBIN 3' OXIME; LEVODOPA; NADPH:QUINONE OXIDOREDUCTASE; NORDIHYDROGUAIARETIC ACID; OXIDOREDUCTASE; PLACEBO; PRAMIPEXOLE; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESORCINOL; ROPINIROLE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

CELL PROTECTION; DRUG DESIGN; DRUG TARGETING; GLUTATHIONE METABOLISM; HOMEOSTASIS; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; UPREGULATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; UP-REGULATION;

EID: 65549095883     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802716501     Document Type: Review

References (113)

1. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28 : 57-87 (Pubitemid 41098899)
2. Jenner P. Oxidative stress and Parkinson's disease. Handb Clin Neurol 2007;83 : 507-520
3. Cuadrado A, Rojo AI. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 2008;14(5):429-442
4. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008;62(4):236-249
5. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37(6):714-722
6. Betarbet R, Greenamyre JT. Parkinson's disease: animal models. Handb Clin Neurol 2007;83 : 265-287
7. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-980 (Pubitemid 13189531)
8. Rojo AI, Montero C, Salazar M, et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 2006;24(7):1874-1884 (Pubitemid 44583472)
9. Kushnareva Y, Murphy AN, Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 2002;368(Pt 2):545-553 (Pubitemid 35454532)
10. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002;22(16):7006-7015 (Pubitemid 35379158)
11. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 2006;96(4):909-916
12. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004;56(3):331-349 (Pubitemid 39096594)
13. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 2000;1(3):181-195
14. Colebrooke RE, Humby T, Lynch PJ, et al. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 2006;24(9):2622-2630 (Pubitemid 44726774)
15. Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007;27(30):8138-8148 (Pubitemid 47173329)
16. Chen L, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008;28(2):425-433
17. Kuhn DM, Arthur RE Jr, Thomas DM, Elferink LA. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 1999;73(3):1309-1317 (Pubitemid 29395493)
18. Whitehead RE, Ferrer JV, Javitch JA, Justice JB. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 2001;76(4):1242-1251 (Pubitemid 32167397)
19. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998;54(5):691-697 (Pubitemid 28546072)
20. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294(5545):1346-1349 (Pubitemid 33063102)
21. Tessari I, Bisaglia M, Valle F, et al. The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease. J Biol Chem 2008;283(24):16808-16817
22. LaVoie MJ, Ostaszewski BL, Weihofen A, et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005;11(11):1214-1221 (Pubitemid 43093669)
23. Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008;28(33):8189-8198
24. Spencer JP, Jenner P, Daniel SE, et al. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998;71(5):2112-2122 (Pubitemid 28491568)
25. Smith PF. Inflammation in Parkinson's disease: an update. Curr Opin Investig Drugs 2008;9(5):478-484 (Pubitemid 351677901)
26. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006;21(2):404-412
27. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60(8):1059-1064 (Pubitemid 36975791)
28. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58(6):963-967 (Pubitemid 41746889)
29. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 2005;7(9-10):1223-1233 (Pubitemid 41232519)
30. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003;278(39):37948-37956 (Pubitemid 37175325)
31. Lee JM, Calkins MJ, Chan K, et al. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278(14):12029-12038 (Pubitemid 36800179)
32. Thimmulappa RK, Mai KH, Srisuma S, et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62(18):5196-5203 (Pubitemid 35033454)
33. Shih AY, Johnson DA, Wong G, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003;23(8):3394-3406 (Pubitemid 36531981)
34. Innamorato NG, Rojo AI, Garcia-Yague AJ, et al. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008;181(1):680-689
35. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004;24(5):1101-1112 (Pubitemid 38177017)
36. Calkins MJ, Johnson DA, Townsend JA, et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 2008 [Epub ahead of print; doi: 10.1089/ars.2008.2241]
37. Clark J, Simon DK. Transcribe to Survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2008 [Epub ahead of print; doi: 10.1089/ars.2008.2241]
38. Yamamoto T, Suzuki T, Kobayashi A, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008;28(8):2758-2770 (Pubitemid 351542373)
39. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004;24(16):7130-7139 (Pubitemid 39014439)
40. Cullinan SB, Gordan JD, Jin J, et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004;24(19):8477-8486 (Pubitemid 39245070)
41. Zhang DD, Lo SC, Cross JV, et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24(24):10941-10953 (Pubitemid 39603148)
42. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005;25(1):162-171 (Pubitemid 40039808)
43. Tong KI, Katoh Y, Kusunoki H, et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 2006;26(8):2887-2900
44. McMahon M, Thomas N, Itoh K, et al. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 2006;281(34):24756-24768
45. Tong KI, Padmanabhan B, Kobayashi A, et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 2007;27(21):7511-7521 (Pubitemid 350033657)
46. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21(5):689-700 (Pubitemid 43290735)
47. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 2004;101(7):2040-2045 (Pubitemid 38229011)
48. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002;99(18):11908-11913 (Pubitemid 34994497)
49. Eggler AL, Luo Y, van Breemen RB, Mesecar AD. Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem Res Toxicol 2007;20(12):1878-1884
50. Luo Y, Eggler AL, Liu D, et al. Sites of alkylation of human Keap1 by natural chemoprevention agents. J Am Soc Mass Spectrom 2007;18(12):2226-2232 (Pubitemid 350161332)
51. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003;23(22):8137-8151 (Pubitemid 37377505)
52. Salazar M, Rojo AI, Velasco D, et al. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 2006;281(21):14841-14851 (Pubitemid 43855189)
53. Rojo AI, Rada P, Egea J, et al. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal celldeath. Mol Cell Neurosci 2008;39(1):125-132
54. Rojo AI, Sagarra MR, Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 2008;105(1):192-202
55. Jain AK, Jaiswal AK. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 2007;282(22):16502-16510 (Pubitemid 47100395)
56. Apopa PL, He X, Ma Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2(CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 2008;22(1):63-76 (Pubitemid 351360163)
57. Martin D, Rojo AI, Salinas M, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004;279(10):8919-8929 (Pubitemid 38295953)
58. Lim JH, Kim KM, Kim SW, et al. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol Res 2008;57(5):325-331
59. Ikeyama S, Kokkonen G, Shack S, et al. Loss in oxidative stress tolerance with aging linked to reduced extracellular signal-regulated kinase and Akt kinase activities. Faseb J 2002;16(1):114-116
60. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005;58(6):829-839 (Pubitemid 41746872)
61. Clements CM, McNally RS, Conti BJ, et al. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006;103(41):15091-15096 (Pubitemid 44583169)
62. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 2008;178(6):592-604
63. Ramsey CP, Glass CA, Montgomery MB, et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007;66(1):75-85 (Pubitemid 46066791)
64. Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006;27(6):1094-1100
65. Jakel RJ, Townsend JA, Kraft AD, Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007;1144 : 192-201 (Pubitemid 46440842)
66. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60(1):79-127
67. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66(10 Suppl 4):S24-36 (Pubitemid 44336999)
68. Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free Radic Biol Med 2004;37(12):1995-2011 (Pubitemid 39491319)
69. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 2004;1012 : 306-325 (Pubitemid 38453534)
70. Saavedra A, Baltazar G, Carvalho CM, Duarte EP. GDNF modulates HO-1 expression in substantia nigra postnatal vcell cultures. Free Radic Biol Med 2005;39(12):1611-1619 (Pubitemid 41642592)
71. Yang W, Tiffany-Castiglioni E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. J Toxicol Environ Health A 2005;68(22):1939-1961 (Pubitemid 41765788)
72. Kim DK, Kim JS, Kim JE, et al. Heme oxygenase-1 induction by dieldrin in dopaminergic cells. Neuroreport 2005;16(5):509-512 (Pubitemid 40477558)
73. Salinas M, Diaz R, Abraham NG, et al. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem 2003;278(16):13898-13904 (Pubitemid 36799930)
74. Talalay P, Dinkova-Kostova AT. Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 2004;382 : 355-364 (Pubitemid 38240799)
75. van Muiswinkel FL, de Vos RA, Bol JG, et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004;25(9):1253-1262 (Pubitemid 39094028)
76. Okada S, Farin FM, Stapleton P, et al. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase(NQO1, NQO2) genes. Neurosci Lett 2005;375(3):178-180 (Pubitemid 40202948)
77. Fong CS, Wu RM, Shieh JC, et al. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. Clin Chim Acta 2007;378(1-2):136-141 (Pubitemid 46241071)
78. Zafar KS, Inayat-Hussain SH, Siegel D, et al. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 2006;166(3):261-267 (Pubitemid 44416555)
79. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33(3):305-310
80. Pearce RK, Owen A, Daniel S, et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 1997;104(6-7):661-677 (Pubitemid 27474680)
81. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142(2):128-130
82. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36(3):348-355 (Pubitemid 24280055)
83. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35(1):38-44 (Pubitemid 24027604)
84. Satoh T, Lipton SA. Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci 2007;30(1):37-45 (Pubitemid 44960491)
85. Dinkova-Kostova AT, Fahey JW, Talalay P. Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol 2004;382 : 423-448 (Pubitemid 38240803)
86. Cao TT, Ma L, Kandpal G, et al. Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage. J Neurochem 2005;95(2):406-417 (Pubitemid 41457509)
87. Trinh K, Moore K, Wes PD, et al. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 2008;28(2):465-472
88. Han JM, Lee YJ, Lee SY, et al. Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 2007;321(1):249-256 (Pubitemid 46456990)
89. Jin F, Wu Q, Lu YF, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 2008;600(1-3):78-82
90. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008;44(5):907-917
91. Bensasson RV, Zoete V, Dinkova-Kostova AT, Talalay P. Two-step mechanism of induction of the gene expression of a prototypic cancer-protective enzyme by diphenols. Chem Res Toxicol 2008;21(4):805-812 (Pubitemid 351644558)
92. Satoh T, Kosaka K, Itoh K, et al. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 2008;104(4):1116-1131 (Pubitemid 351143643)
93. Kweon MH, Adhami VM, Lee JS, Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 2006;281(44):33761-33772 (Pubitemid 46036754)
94. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008;269(2):315-325
95. Guzman-Beltran S, Espada S, Orozco-Ibarra M, et al. Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress. Neurosci Lett 2008;477(2-3):167-171
96. Mattson MP, Cheng A. Neurohormetic phytochemicals: Low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 2006;29(11):632-639 (Pubitemid 44602260)
97. Tirmenstein MA, Hu CX, Scicchitano MS, et al. Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol In Vitro 2005;19(4):471-479 (Pubitemid 40501713)
98. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 2006 ;(70):419-426 (Pubitemid 44622232)
99. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61(7):1044-1053 (Pubitemid 38915945)
100. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54(1):93-101 (Pubitemid 36764985)
101. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J Anti Aging Med 2003;6(1):21-28 (Pubitemid 36627197)
102. Picada JN, Roesler R, Henriques JA. Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine. Braz J Med Biol Res 2005;38(4):477-486 (Pubitemid 40691997)
103. Hara H, Ohta M, Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 2006;84(4):860-866 (Pubitemid 44366687)
104. Kim SJ, Kim JS, Cho HS, et al. Carnosol, a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells. Neuroreport 2006;17(16):1729-1733 (Pubitemid 44621573)
105. Park JA, Kim S, Lee SY, et al. Beneficial effects of carnosic acid on dieldrin-induced dopaminergic neuronal cell death. Neuroreport 2008;19(13):1301-1304
106. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2006;9(3 Suppl):309-317 (Pubitemid 44253325)
107. Suh JH, Shenvi SV, Dixon BM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 2004;101(10):3381-3386 (Pubitemid 38338203)
108. Wang W, Yang Y, Ying C, et al. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007;52(8):1678-1684 (Pubitemid 46843143)
109. Kozikowski AP, Gaisina IN, Petukhov PA, et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 2006;1(2):256-266
110. Wu Y, Shang Y, Sun S, et al. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase- 3 mediated signaling pathway. Apoptosis 2007;12(8):1365-1375 (Pubitemid 46988273)
111. Yu Y, Wang JR, Sun PH, et al. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action. J Neurochem 2008;104(4):946-956 (Pubitemid 351146579)
112. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007;25(1):35-44 (Pubitemid 44765215)
113. Nakaso K, Nakamura C, Sato H, et al. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 2006;339(3):915-922 (Pubitemid 41772899)